Company / Operating Cash Flow
Cue Biopharma, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$21.7M
FY2025
5-year range
-$41.8M / -$21.7M
FY2021-FY2025
Trend
+40.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has increased for 3 consecutive years, from -$42M in FY2022 to -$22M in FY2025.
Based on SEC 10-K filings.
-$22M in FY2025.
Improved from -$40M to -$22M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Cue Biopharma, Inc.'s operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 40.3% year-over-year.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$21.7M | +40.3% |
| FY2024 | -$36.3M | +9.1% |
| FY2023 | -$40.0M | +4.4% |
| FY2022 | -$41.8M | -7.6% |
| FY2021 | -$38.8M | -26.1% |
| FY2020 | -$30.8M | -16.6% |
| FY2019 | -$26.4M | -117.5% |
| FY2018 | -$12.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026